DR. DONALD ANTHONY RICHARDS MD NPI 1659313559

NPI Details

DR. Donald Anthony Richards, MD is a medical oncology internal medicine in Tyler, TX with 42 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Donald Anthony Richards, MD NPI is 1659313559. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF TEXAS MEDICAL SCHOOL AT SAN ANTONIO
Graduation Year:1983

The provider's business location address is:

501 SAUNDERS AVE STE 200
TYLER, TX
ZIP 75702-524
Phone: (903) 579-9800
Fax: (903) 592-5988

The NPI 1659313559 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, levoleucovorin, not otherwise specified, 0.5 mg (HCPCS:J0641)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session (HCPCS:G6015)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Iron binding capacity (HCPCS:83550)
• Ferritin (blood protein) level (HCPCS:82728)
• Magnesium level (HCPCS:83735)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Iron level (HCPCS:83540)
• Unclassified drugs (HCPCS:J3490)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Ct scan of chest with contrast (HCPCS:71260)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Urea nitrogen level to assess kidney function, quantitative (HCPCS:84520)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev (HCPCS:G6013)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Liver enzyme (sgot), level (HCPCS:84450)
• Liver enzyme (sgpt), level (HCPCS:84460)
• Albumin (protein) level (HCPCS:82040)
• Total protein level, blood (HCPCS:84155)
• Phosphatase (enzyme) level, alkaline (HCPCS:84075)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev (HCPCS:G6012)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Ct scan of chest without contrast (HCPCS:71250)
• Ct scan of abdomen and pelvis before and after contrast (HCPCS:74178)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Red blood count, automated test (HCPCS:85045)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Ct scan of soft tissue of neck with contrast (HCPCS:70491)

The enumeration date for this NPI number is 6/12/2006 and was last updated on 7/8/2023.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.